Axion BioSystems, Inc., the world leader in multi-well microelectrode array (MEA) systems, has announced REPROCELL as the new distributor of its Maestro systems and consumables in Japan.
The lab-scale system will allow researchers to study and culture stem cells in suspension
Glasgow, UK: REPROCELL Europe Ltd today announced exclusive distribution rights to a single-use reactor series for stem cell culture in 11 European countries*. The ABLE Biott Bioreactor System is a lab-scaled bioreactor that offers a new way for stem cell researchers to study and culture pluripotent stem cells.
“We are excited to offer our customers the chance to access this innovative new bioreactor, which is ideal for the culture of pluripotent stem cells” said Dr David Bunton, CEO at REPROCELL Europe Ltd. “The product has been rapidly and widely adopted by stem cell scientists in Japan and the US, with the recent CE marking now enabling its use in Europe”.
Yokohama Japan – REPROCELL Inc. today announced that it has established the current good manufacturing practice (cGMP) cell processing suite at Life Innovation Center (LIC) in Tonomachi area in Kawasaki City for production of iPS Cell-derived Glial Progenitors (iGRP) for treatment of CNS disorders. The suite has been designed to support Clinical Trials of cell therapy products.
Wave 3 of the UK Government’s science and innovation audits (SIAs) have been published today, identifying a number of strengths in different industries across the country — including precision medicine innovation in Scotland, led by the University of Glasgow.
Glasgow UK, 12 March 2019 – REPROCELL Europe Ltd (REPROCELL), a UK-based human tissue research company, today announced a strategic partnership with Medicines Discovery Catapult.
BELTSVILLE, MD. — REPROCELL Inc. and Fox Chase, Ltd., a member of the Fox Chase Cancer Center family of organizations, have formed a joint venture to begin operations of multi-site biosample repository facilities globally. The new Delaware-based joint venture company, Biorepository LLC, will act as a hub to manage its global subsidiaries, and its first subsidiary will be established in India in March.
Funding will be used to improve efficiency of induced pluripotent stem cell production
Sign up to receive information from REPROCELL about our products, services, applications, promotions, and news (includes a weekly blog update email).